We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SWK Holdings Corporation | NASDAQ:SWKH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.80 | 15.85 | 16.63 | 16.18 | 15.80 | 15.80 | 443 | 16:02:07 |
DALLAS, July 17, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners.
"During the second quarter of 2023 SWK advanced our 2023 objectives including securing a new four-year credit facility with First Horizon Bank with $45 million committed at close," stated Jody Staggs, President and CEO of SWK. "This credit facility enables us to be a reliable source of funding for our borrower partners during a time when capital available to the life sciences sector is facing pressure. We remain focused on growing our value per share and during the second quarter we repurchased 272,492 shares for $4.6 million, or $16.88 per share. Year-to-date we have repurchased over 301,000 shares for $5.1 million, or $17.03 per share. We view repurchasing shares at the current discount to book as a highly accretive use of capital that benefits shareholders."
Mr. Staggs continued: "Despite macroeconomic headwinds, the majority of our portfolio continues to perform as expected, and SWK remains well positioned due to our focus on financing differentiated life science companies that address unmet medical needs, which we believe will capture market share. Our healthy balance sheet with minimal leverage and ongoing share repurchase program provides us bandwidth to continue to deploy capital in companies that have the potential to drive health care innovation and deliver positive returns to our shareholders."
SWK Holdings Portfolio Updates
Flowonix Medical
During June, Algorithm Sciences, Inc. purchased the assets of Flowonix Medical. SWK has received $1.5mm of proceeds from the sale and anticipates receiving approximately $0.5 million in additional proceeds from the estate. SWK will also receive royalties on sales of the Prometra pump for existing indications as well as royalties on sales of Algorithm's PulmoProst therapy for Pulmonary Arterial Hypertension, which uses the Prometra pump.
SWK will provide an update on the Flowonix finance receivable in our second quarter earnings release.
SWK Holdings Borrower Partner Achievements
Aziyo Biologics, Inc.
Aziyo Biologics (Nasdaq: AZYO) is a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat.
Biolase, Inc.
Biolase (Nasdaq: BIOL) is a medical device company that develops, manufactures, and markets proprietary dental laser systems.
Biotricity, Inc.
Biotricity (Nasdaq: BTCY) is a medical technology company focused on delivering remote biometric monitoring solutions to the medical and consumer markets.
Coflex Royalty
Coflex is an interlaminar stabilization device used after an open decompression that can be performed in various settings, offering a non-fusion treatment option for lumbar spinal stenosis (LSS) patients.
Eton Pharmaceuticals, Inc.
Eton (Nasdaq: ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
Exeevo, Inc.
Exeevo is a global enterprise SaaS leader for life sciences focused on elevating and transforming customer experiences.
FC2 Royalty
FC2 Female Condom is a female-initiated birth control offering dual protection against STIs and unwanted pregnancy.
MedMinder
MedMinder is a leading fully integrated, end-to-end pharmacy, medication adherence, and connected care solution for seniors and polypharmacy patients.
MolecuLight, Inc.
MolecuLight Inc. is a leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds.
Neolight, Inc.
NeoLight is a medical device company focused on developing and marketing technologies for treating preventable conditions in the newborn care market.
About SWK Holdings Corporation
SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, whose Peptelligence® and ProPerma® drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors which, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/swk-holdings-highlights-recent-achievements-and-provides-portfolio-update-301878952.html
SOURCE SWK Holdings Corporation
Copyright 2023 PR Newswire
1 Year SWK Chart |
1 Month SWK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions